1. Home
  2. CHMI vs MAIA Comparison

CHMI vs MAIA Comparison

Compare CHMI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.50

Market Cap

93.0M

Sector

Real Estate

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.34

Market Cap

89.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMI
MAIA
Founded
2012
2018
Country
United States
United States
Employees
14
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.0M
89.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CHMI
MAIA
Price
$2.50
$1.34
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
234.8K
744.4K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
15.81%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$59.20
N/A
P/E Ratio
$139.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$0.87
52 Week High
$3.14
$3.19

Technical Indicators

Market Signals
Indicator
CHMI
MAIA
Relative Strength Index (RSI) 42.14 36.19
Support Level $2.52 $1.26
Resistance Level $2.74 $1.74
Average True Range (ATR) 0.10 0.09
MACD -0.03 0.00
Stochastic Oscillator 32.50 21.43

Price Performance

Historical Comparison
CHMI
MAIA

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: